Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
17 avr. 2019 16h25 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
08 avr. 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
18 mars 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
07 mars 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two...
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
28 févr. 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference on...
Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
26 févr. 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March...
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
03 janv. 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various...
Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
17 déc. 2018 08h36 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
11 déc. 2018 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
01 nov. 2018 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing into multiple chronic...